
AI-designed drug hints at reversing aging signals in IPF patients
In a small 12-week study of rentosertib for idiopathic pulmonary fibrosis, six independent aging clocks all indicated the patients' blood appeared biologically younger, with four-week reductions of about 2.7–3.5 years on some clocks, but the findings are limited by the small sample size and potential disease-improvement effects, so they do not prove anti-aging effects and require larger, longer trials.








